Lorcaserin: A Review of its Use in Chronic Weight Management
Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand, . Drugs
(Impact Factor: 4.34).
03/2013; 73(5). DOI: 10.1007/s40265-013-0035-1
Oral lorcaserin (BELVIQ(®)), a selective serotonin 5-HT2C receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes). This article reviews the pharmacological properties, therapeutic efficacy and tolerability of oral lorcaserin in this patient population. In three large randomized, double-blind, multicentre studies, oral lorcaserin was more effective than placebo in the management of obese and overweight adults with or without type 2 diabetes mellitus. Following 12 months' therapy, significantly higher proportions of lorcaserin than placebo recipients achieved a ≥5 and ≥10 % reduction from baseline in their bodyweight and a significant between-group difference favouring lorcaserin over placebo was observed for the change from baseline in bodyweight. Moreover, among patients who had achieved a ≥5 % reduction in their bodyweight after 12 months' therapy with lorcaserin, a significantly higher proportion who received lorcaserin for a further 12 months than those who switched to placebo maintained ≥5 % weight loss at 24 months. In general, oral lorcaserin was well tolerated in clinical studies, with hypoglycaemia and headache the most frequently reported adverse events in those with or without type 2 diabetes, respectively. According to a pooled analysis, the risk of US-FDA-defined valvulopathy with lorcaserin is generally low and not statistically significantly different from placebo. From these and other data, the FDA has concluded that lorcaserin is unlikely to elevate the risk of valvulopathy.
Available from: link.springer.com
- "Lorcaserin, a novel selective agonist of the 5-hydroxytryptamine (2C) receptor, is purported to reduce weight by decreasing food consumption and increasing satiety. Of note, preclinical and clinical studies indicate lorcaserin, unlike fenfluramine and dexfenfluramine, which also act on serotonin metabolism, is not associated with cardiac valvulopathy or risk of pulmonary hyperten- sion[14,15]. Lorcaserin is approved for chronic weight loss management in adults as an adjunct to diet and exercise . "
[Show abstract] [Hide abstract]
ABSTRACT: Oral lorcaserin (Belviq®), a novel selective serotonin 5-HT2C receptor agonist, is indicated in the USA as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management of obese adults, or overweight adults with at least one weight-related co-morbidity. In 12-month clinical studies, lorcaserin was more effective than placebo in reducing weight in obese or overweight adults with or without type 2 diabetes mellitus. It is well tolerated and does not appear to be associated with an increased risk of valvulopathy.
Available from: Baptist Gallwitz
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.